-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-996 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-996 in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-996 in Obesity Drug Details: CT-996 (RG6652) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-996 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-996 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-996 in Type 2 Diabetes Drug Details: CT-996 (RG6652) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-388 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-388 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-388 in Type 2 Diabetes Drug Details: CT-388 (RG6640) is under...
-
Thematic Analysis
Pharma M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Pharma Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-868 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-868 in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-868 in Obesity Drug Details: CT-868 (RG6641) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-868 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-868 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-868 in Type 2 Diabetes Drug Details: CT-868 (RG6641) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-868 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-868 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-868 in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dupilumab in Pruritus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Pruritus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dupilumab in Pruritus Drug Details: Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis) is a monoclonal...
-
Product Insights
Prader-Willi Syndrome (PWS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) - Drugs In Development, 2023’, provides an overview of the Prader-Willi Syndrome (PWS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...